Abeona Therapeutics Inc. (ABEO)
| Market Cap | 303.18M |
| Revenue (ttm) | 5.82M |
| Net Income (ttm) | 71.18M |
| Shares Out | 56.88M |
| EPS (ttm) | 1.01 |
| PE Ratio | 5.27 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,788 |
| Open | 5.32 |
| Previous Close | 5.34 |
| Day's Range | 5.32 - 5.40 |
| 52-Week Range | 4.00 - 7.54 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+275.24%) |
| Earnings Date | May 14, 2026 |
About ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 275.24% from the latest price.
News
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effectiv...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa...
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as th...
Abeona Therapeutics Earnings Call Transcript: Q4 2025
ZEVASKYN's commercial launch is ramping up with strong patient demand, robust payer coverage, and expanding treatment center network. 2025 saw a return to profitability driven by a major voucher sale, and operational execution in 2026 is expected to drive further growth.
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of...
Abeona Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Launch momentum is strong following resolution of manufacturing issues, with four centers active and plans to expand to five to seven this year. Over 50 patients have been identified, high conversion rates are seen, and manufacturing capacity is scaling to meet demand. Profitability is targeted for 2026 with continued process optimization.
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene z...
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth qu...
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer ...
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qual...
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a firs...
Abeona Therapeutics Transcript: Stifel 2025 Healthcare Conference
ZEVASKYN's commercial launch is progressing with strong demand, expanding QTC network, and improved manufacturing processes. Reimbursement is robust with a new J Code and full Medicaid coverage. Pipeline advances include an FDA-endorsed ophthalmology program, with profitability expected in early 2026.
Abeona Therapeutics Earnings Call Transcript: Q3 2025
Operational progress continued with ZEVASKYN's launch, despite a Q4 2025 shift for first patient treatment due to assay optimization. Patient demand and QTC network doubled, broad payer coverage achieved, and profitability is projected for the first half of 2026.
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
- First anticipated ZEVASKYN ® patient treatment shifted to 4Q 2025 following implementation of optimized release assay -
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third...
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announ...
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announ...
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies RDEA Pilot Program provides sponsors enhanced communication a...
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
CLEVELAND, Ohio and AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Children's Hospital Colorado today announced activation of Children's Colorado as the n...
Abeona Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
ZevaSkin™ launched as the first gene therapy for RDEB, showing strong demand, positive payer coverage, and multi-year healing benefits. With a $4 billion market opportunity and profitability projected in early 2026, manufacturing and patient access are being rapidly scaled.
Abeona Therapeutics Transcript: Cantor Global Healthcare Conference 2025
ZEVASKYN's commercial launch for rDEB is seeing strong early demand, broad payer coverage, and rapid patient uptake, with manufacturing and treatment capacity scaling to meet needs. Repeat treatments are anticipated, and a robust pipeline is in development.
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September ...
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystro...
Abeona Therapeutics Earnings Call Transcript: Q2 2025
FDA approval and early launch of ZEVASKYN for RDEB drove strong patient and payer interest, with first revenues expected in Q3 2025 and profitability projected for early 2026. Financials were boosted by a PRV sale, and manufacturing capacity is set to expand by mid-2026.
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partn...